Meeting Banner
Abstract #2072

Multiple Sclerosis lesion fingerprint using multicontrast MRI

Guillaume Bonnier 1,2 , Alexis Roche 1,3 , David Romanasco 4 , Samanta Simioni 2 , Djalel-Eddine Meskaldji 4 , David Rotzinger 3 , Ying-Chia Lin 5 , Gloria Menegaz 5 , Myriam Schluep 2 , Renaud Du Pasquier 2 , Tilman Johannes Sumpf 6 , Jens Frahm 6 , Jean-Philippe Thiran 4 , Gunnar Krueger 1,7 , and Cristina Granziera 1,2

1 Advanced Clinical Imaging technology group, Siemens-CIBM, EPFL, Lausanne, Vaud, Switzerland, 2 Department of Clinical Neurosciences, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Vaud, Switzerland, 3 Department of Radiology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Vaud, Switzerland, 4 STI / IEL / LTS5, EPFL, Lausanne, Vaud, Switzerland, 5 Dept. of Computer Science, University of Verona, Itlay, Italy, 6 Biomedizinische NMR Forschungs GmbH, Max Planck Institute for Biophysical Chemistry, Gottingen, Germany, Germany, 7 Healthcare Sector IM&WS S, Siemens Schweiz AG, Lausanne, Vaud, Switzerland

Conventional magnetic resonance imaging (MRI) measures of multiple sclerosis patients provide limited information about the nature and the extent of brain damage and repair. We established a clinically compatible protocol including quantitative MRI techniques (qMRI, T1, T2, T2* relaxometry) and semiquantitative Magnetisation Transfer Imaging to provide a comprehensive MRI fingerprint (CMF) of lesions that is more adherent to the real underlying pathology and to assess the CMF contribution to clinical performances in patients. Lesions characteristics, revealed by combination of q/sq MRI, highly correlated with patients clinical performance and more severe lesions appeared to drive the clinic-radiological correlations.

This abstract and the presentation materials are available to members only; a login is required.

Join Here